MedElevator
Войти в исследования Journal of neurology · 2026
Cerebral venous sinus thrombosis risk across various oral contraceptives: a disproportionality analysis of the FDA adverse event reporting system.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balshi Alexandra
Аннотация
OBJECTIVE: Estrogen-containing oral contraceptives (OCPs) increase the risk of thromboembolic events including cerebral venous sinus thromboses (CVSTs). However, robust pharmacovigilance data comparing CVST risk across OCPs remain limited.
STUDY DESIGN: The FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting.
RESULTS: There were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases).
CONCLUSION: Clinicians should educate those taking estrogen-containing OCPs on how to identify CVST symptoms.
STUDY DESIGN: The FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting.
RESULTS: There were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases).
CONCLUSION: Clinicians should educate those taking estrogen-containing OCPs on how to identify CVST symptoms.